Successfully treated with siltuximab and prednisone in a 7-year-old girl with DOCK8-deficiency presenting as recurrent wart-like lesions: a case report

Front Immunol. 2024 Jul 9:15:1414573. doi: 10.3389/fimmu.2024.1414573. eCollection 2024.

Abstract

Dedicator of cytokinesis 8 (DOCK8) deficiency represents a primary immunodeficiency with a wide range of clinical symptoms, including recurrent infections, atopy, and increased malignancy risk. This study presents a case of a 6-year-old girl with DOCK8 deficiency, characterized by severe, treatment-resistant herpetic infections who was successfully treated with siltuximab and glucocorticoids. The successful use of siltuximab in achieving remission highlights the pivotal role of interleukin-6 (IL-6) in DOCK8 deficiency pathogenesis and suggests that IL-6 modulation can be critical in managing DOCK8 deficiency-related viral infections, which may inform future therapeutic strategies for DOCK8 deficiency and similar immunodeficiencies.

Keywords: DOCK8 deficiency; IL-6; herpetic infections; primary immunodeficiency; siltuximab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal
  • Child
  • Female
  • Guanine Nucleotide Exchange Factors* / deficiency
  • Guanine Nucleotide Exchange Factors* / genetics
  • Humans
  • Interleukin-6
  • Prednisone* / therapeutic use
  • Recurrence
  • Treatment Outcome
  • Warts / diagnosis
  • Warts / drug therapy

Substances

  • DOCK8 protein, human
  • Guanine Nucleotide Exchange Factors
  • siltuximab
  • Prednisone
  • Interleukin-6
  • Antibodies, Monoclonal

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This publication presents independent research funded by the Medical-Engineering Cross Fund of Shanghai Jiao Tong University(YG2021QN57), National Nature Science Foundation of China (82203962). There was no commercial support for this study.